Fiona Lawrence
Conseiller Juridique Général chez ARECOR THERAPEUTICS PLC
Fortune : 123 061 $ au 30/04/2024
Profil
Fiona Jane Lawrence is currently the VP-Clinical Development & Regulatory Affairs at Arecor Therapeutics Plc.
Previously, she worked as the Director-Research & Clinical Development at Duchenne UK, Senior Manager-Clinical Research at Prosensa Therapeutics BV, Commercial Trials Manager at Cambridge University Hospitals NHS Foundation Trust, and Senior Manager-Clinical Research at BioMarin Nederland BV.
Ms. Lawrence has an undergraduate degree from the University of Bath and a graduate degree from the University of Surrey.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARECOR THERAPEUTICS PLC
0,24% | 16/11/2022 | 72 000 ( 0,24% ) | 123 061 $ | 30/04/2024 |
Postes actifs de Fiona Lawrence
| Sociétés | Poste | Début |
|---|---|---|
| ARECOR THERAPEUTICS PLC | Conseiller Juridique Général | - |
Anciens postes connus de Fiona Lawrence
| Sociétés | Poste | Fin |
|---|---|---|
| Cambridge University Hospitals NHS Foundation Trust | Corporate Officer/Principal | - |
| BioMarin Nederland BV | Corporate Officer/Principal | - |
| Prosensa Therapeutics BV | Corporate Officer/Principal | - |
Duchenne UK
 Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Duchenne UK is a UK-based charity that focuses on finding effective treatments for Duchenne muscular dystrophy (DMD), a progressive condition that weakens all the muscles in the body and is diagnosed in childhood. Additionally, Duchenne connects and supports families affected by DMD. The charity funds research that aims to provide treatments for those affected by DMD and removes roadblocks that prevent patients from accessing the treatments they need. The British company was founded in 2012 by Nick Crossley, Emily Crossley, and Alex Johnson, and Emily Crossley and Alex Johnson have been the CEOs since 2012. | Directeur Technique/Scientifique/R&D | - |
Formation de Fiona Lawrence
| University of Bath | Undergraduate Degree |
| University of Surrey | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ARECOR THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 4 |
|---|---|
| Prosensa Therapeutics BV | Health Technology |
| BioMarin Nederland BV | |
Duchenne UK
Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Duchenne UK is a UK-based charity that focuses on finding effective treatments for Duchenne muscular dystrophy (DMD), a progressive condition that weakens all the muscles in the body and is diagnosed in childhood. Additionally, Duchenne connects and supports families affected by DMD. The charity funds research that aims to provide treatments for those affected by DMD and removes roadblocks that prevent patients from accessing the treatments they need. The British company was founded in 2012 by Nick Crossley, Emily Crossley, and Alex Johnson, and Emily Crossley and Alex Johnson have been the CEOs since 2012. | Miscellaneous |
| Cambridge University Hospitals NHS Foundation Trust | Health Services |
